16-hydroxyprednisolone, also known as **prednisolone 16-alpha-hydroxylate**, is a synthetic corticosteroid that is a metabolite of prednisolone. It is a potent anti-inflammatory agent that is structurally similar to prednisolone, but with a hydroxyl group added at the 16α position.
**Importance in Research:**
16-hydroxyprednisolone is important for research due to its potential pharmacological and biological implications:
* **Increased Potency:** It has been shown to possess significantly higher anti-inflammatory potency than prednisolone in some studies. This increased potency could make it a more effective therapeutic agent for certain conditions.
* **Selective Action:** Research suggests that 16-hydroxyprednisolone may have more selective actions than prednisolone, potentially targeting specific pathways or cell types involved in inflammation.
* **Metabolic Pathways:** Studying 16-hydroxyprednisolone helps researchers understand the metabolism and bioactivation of prednisolone and other corticosteroids. This knowledge can aid in optimizing drug delivery and therapeutic efficacy.
* **Drug Development:** 16-hydroxyprednisolone can serve as a starting point for the development of novel corticosteroids with enhanced therapeutic properties and fewer side effects.
* **Disease Mechanisms:** Researching its effects on various cell types and systems can provide insights into the mechanisms of inflammatory and autoimmune diseases, potentially leading to new therapeutic targets.
**Note:** While research into 16-hydroxyprednisolone is promising, it is not currently used clinically as a medication. Further research is needed to fully understand its therapeutic potential and safety profile.
16-hydroxyprednisolone: metabolite of budesonide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
16-hydroxyprednisolone : A 16-hydroxy steroid that is prednisolone carrying a hydroxy group at the 16 position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 129734732 |
| MeSH ID | M0245817 |
| Synonym |
|---|
| 16-hydroxyprednisolone |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The purpose of this study was to evaluate the presystemic extraction and pharmacodynamic action of buccal budesonide." | ( Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Bertz, H; Dilger, K; Finke, J; Gratwohl, A; Halter, J; Lopez-Lazaro, L, 2009) | 0.35 |
| " The influence of hyperhydration on the plasma and urinary pharmacokinetic (PK) profiles of BDS and metabolites was also examined." | ( Effect of hyperhydration on the pharmacokinetics and detection of orally administered budesonide in doping control analysis. Al-Maadheed, M; Athanasiadou, I; Dokoumetzidis, A; Georgakopoulos, C; Mbeloug, M; Saleh, A; Valsami, G; Vonaparti, A, 2019) | 0.51 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide." | ( Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Bertz, H; Dilger, K; Finke, J; Gratwohl, A; Halter, J; Lopez-Lazaro, L, 2009) | 0.35 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide." | ( Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Bertz, H; Dilger, K; Finke, J; Gratwohl, A; Halter, J; Lopez-Lazaro, L, 2009) | 0.35 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||